What is the duration of action of hydromorphone (extended release)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Duration of Action of Hydromorphone Extended Release

Extended-release hydromorphone has a duration of action of 12-24 hours, depending on the specific formulation, with most common formulations designed for twice-daily (12-hour) dosing. 1, 2

Pharmacokinetic Properties

Extended-release hydromorphone formulations are designed to provide sustained analgesia through controlled drug delivery systems:

  • Most extended-release hydromorphone products utilize osmotic technology (OROS) to deliver consistent plasma concentrations over 24 hours 2, 3
  • The controlled-release capsule formulation is specifically designed for twice-daily (every 12 hours) administration 1
  • Steady-state plasma levels are typically achieved within 48-72 hours after initiation of therapy 2

Clinical Applications

Extended-release hydromorphone is indicated for:

  • Management of moderate to severe chronic pain requiring continuous, around-the-clock opioid analgesia for an extended period
  • Patients with stable opioid requirements who need sustained analgesia 3

Dosing Considerations

When converting patients to extended-release hydromorphone:

  • The values for absorption, bioavailability, and maximum plasma concentration after administration of controlled-release hydromorphone every 12 hours are equivalent to those of immediate-release tablets given every 4 hours (at three times the dose) 1
  • When converting from immediate-release to extended-release formulations, the same total daily dose can be used, divided into once or twice daily dosing depending on the formulation 4
  • A 5:1 morphine-to-hydromorphone conversion ratio is typically used when switching from oral morphine to extended-release hydromorphone 2

Safety Considerations

Important precautions when using extended-release hydromorphone:

  • Patients should be monitored for respiratory depression, particularly during initiation and dose titration 5
  • The risk of respiratory depression is significantly higher with intravenous administration compared to oral administration 5
  • Breakthrough pain during extended-release therapy may require supplemental immediate-release opioid medication 2, 3
  • Dose stabilization (defined as a 3-day period with unchanged daily dose and ≤3 doses of rescue medication) is typically achieved within 12 days (range 3-33 days) 2

Comparative Efficacy

When comparing hydromorphone to other opioids:

  • Hydromorphone is approximately 5-7 times more potent than oral morphine 6
  • For acute pain management, hydromorphone (0.015 mg/kg IV) is considered comparable or potentially superior to morphine (0.1 mg/kg IV) due to its quicker onset of action 6
  • Extended-release hydromorphone provides consistent plasma concentrations and sustained around-the-clock analgesia, making it well-suited for long-term pain management 3

Common Pitfalls

To avoid complications when using extended-release hydromorphone:

  • Do not confuse immediate-release and extended-release formulations, as this can lead to significant overdose
  • Extended-release formulations should never be crushed, chewed, or dissolved as this destroys the controlled-release mechanism and can lead to rapid absorption and overdose
  • Careful dose conversion is essential when switching between different opioids or formulations 5
  • Regular assessment of pain control, side effects, and continued need for opioid therapy is necessary during long-term use 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.